NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $52,567 | -27.6% | 88,259 | -30.1% | 0.00% | – |
| Q2 2023 | $72,589 | -93.5% | 126,197 | -92.1% | 0.00% | – |
| Q1 2023 | $1,121,976 | -69.6% | 1,596,210 | -2.2% | 0.00% | -100.0% |
| Q4 2022 | $3,686,953 | -33.0% | 1,631,395 | -5.1% | 0.00% | 0.0% |
| Q3 2022 | $5,502,000 | -14.3% | 1,719,478 | +1.8% | 0.00% | 0.0% |
| Q2 2022 | $6,419,000 | -33.5% | 1,689,163 | -5.7% | 0.00% | -50.0% |
| Q1 2022 | $9,652,000 | -58.0% | 1,790,742 | +5.2% | 0.00% | -50.0% |
| Q4 2021 | $23,003,000 | -25.5% | 1,702,700 | -0.9% | 0.00% | -33.3% |
| Q3 2021 | $30,863,000 | +4.0% | 1,718,385 | -0.6% | 0.01% | 0.0% |
| Q2 2021 | $29,665,000 | -13.9% | 1,728,702 | +0.4% | 0.01% | -14.3% |
| Q1 2021 | $34,440,000 | +16.9% | 1,722,058 | -0.6% | 0.01% | +16.7% |
| Q4 2020 | $29,463,000 | -0.9% | 1,733,073 | -3.3% | 0.01% | -14.3% |
| Q3 2020 | $29,733,000 | -30.9% | 1,792,202 | -3.5% | 0.01% | -36.4% |
| Q2 2020 | $43,030,000 | +33.9% | 1,857,924 | +3.2% | 0.01% | 0.0% |
| Q1 2020 | $32,138,000 | -18.7% | 1,800,467 | -1.7% | 0.01% | +10.0% |
| Q4 2019 | $39,529,000 | +46.1% | 1,831,292 | +23.3% | 0.01% | +42.9% |
| Q3 2019 | $27,052,000 | -48.6% | 1,485,169 | +0.4% | 0.01% | -50.0% |
| Q2 2019 | $52,637,000 | +8.5% | 1,479,386 | +2.4% | 0.01% | 0.0% |
| Q1 2019 | $48,526,000 | +4.1% | 1,444,210 | +1.8% | 0.01% | -6.7% |
| Q4 2018 | $46,634,000 | -45.4% | 1,418,699 | +1.3% | 0.02% | -31.8% |
| Q3 2018 | $85,406,000 | +50.8% | 1,401,029 | +20.8% | 0.02% | +46.7% |
| Q2 2018 | $56,639,000 | -58.6% | 1,159,918 | -10.0% | 0.02% | -60.5% |
| Q1 2018 | $136,924,000 | +16.1% | 1,288,568 | -34.8% | 0.04% | +22.6% |
| Q4 2017 | $117,939,000 | +138.3% | 1,974,858 | -4.2% | 0.03% | +121.4% |
| Q3 2017 | $49,493,000 | +18.4% | 2,062,186 | -3.6% | 0.01% | +16.7% |
| Q2 2017 | $41,812,000 | -16.2% | 2,138,632 | +0.6% | 0.01% | -14.3% |
| Q1 2017 | $49,895,000 | +107.6% | 2,125,902 | +8.5% | 0.01% | +100.0% |
| Q4 2016 | $24,032,000 | -23.4% | 1,958,602 | +7.3% | 0.01% | -22.2% |
| Q3 2016 | $31,355,000 | +24.6% | 1,825,071 | +3.2% | 0.01% | +12.5% |
| Q2 2016 | $25,173,000 | -4.6% | 1,768,992 | -7.8% | 0.01% | 0.0% |
| Q1 2016 | $26,379,000 | -16.3% | 1,918,587 | +2.6% | 0.01% | -20.0% |
| Q4 2015 | $31,499,000 | +61.2% | 1,869,414 | +4.9% | 0.01% | +66.7% |
| Q3 2015 | $19,537,000 | +5.5% | 1,782,546 | +20.4% | 0.01% | +20.0% |
| Q2 2015 | $18,527,000 | -31.9% | 1,480,958 | -40.1% | 0.01% | -28.6% |
| Q1 2015 | $27,218,000 | -48.8% | 2,474,410 | -27.8% | 0.01% | -50.0% |
| Q4 2014 | $53,124,000 | +24.0% | 3,427,329 | -3.4% | 0.01% | +16.7% |
| Q3 2014 | $42,841,000 | -52.9% | 3,549,480 | -50.0% | 0.01% | 0.0% |
| Q2 2014 | $90,944,000 | +114.8% | 7,093,794 | +103.1% | 0.01% | 0.0% |
| Q1 2014 | $42,341,000 | +10.8% | 3,493,536 | +3.8% | 0.01% | +9.1% |
| Q4 2013 | $38,199,000 | -29.8% | 3,365,468 | -35.4% | 0.01% | +37.5% |
| Q3 2013 | $54,378,000 | +57.7% | 5,206,108 | +74.4% | 0.01% | -27.3% |
| Q2 2013 | $34,473,000 | – | 2,984,722 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |